Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management (Q35526652)

8 August 2017

1 reference

title

Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management (English)

1 reference

8 August 2017

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Charles D Murray

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Andrew Kenneth Burroughs

4

object named as

Andrew Kenneth Burroughs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Roberta Elisa Rossi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ioanna Parisi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Edward John Despott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Dario Conte

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mark Ian Hamilton

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

1 December 2014

1 reference

25516646

World Journal of Gastroenterology

8 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

17352-17359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations

11 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Tumor necrosis factor inhibitors for inflammatory bowel disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Mucosal healing in inflammatory bowel diseases: a systematic review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Causality assessment of drug-induced hepatotoxicity: promises and pitfalls

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Certolizumab pegol for the treatment of Crohn's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Infliximab for induction and maintenance therapy for ulcerative colitis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Recognizing drug-induced liver injury: current problems, possible solutions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Infliximab maintenance therapy for fistulizing Crohn's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Intestinal cancer risk and mortality in patients with Crohn's disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Guidelines for the management of inflammatory bowel disease in adults

27 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

[Infliximab-induced hepatitis during treatment of vulvar Crohn's disease].

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Infliximab induces increase in triglyceride levels in psoriatic arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

A case of infliximab-related liver damage -case report and literature review

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Liver dysfunction in celiac disease.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Serious liver disease induced by infliximab

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Disease activity courses in a regional cohort of Crohn's disease patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4265593

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

26 September 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I46.17352

Clinically significant liver injury in patients treated with natalizumab

21 January 2018

1 reference

12 December 2020

EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease

1 reference

12 December 2020

Infliximab-associated reversible cholestatic liver disease

1 reference

12 December 2020

Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al

1 reference

12 December 2020

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

1 reference

12 December 2020

Autoimmune hepatitis in two psoriasis patients treated with inflixmab

1 reference

12 December 2020

Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab

1 reference

12 December 2020

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease

1 reference

12 December 2020

Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohnʼs Disease with no Relapse After Switching to Adalimumab

1 reference

12 December 2020

Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report

1 reference

12 December 2020

Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case

1 reference

12 December 2020

Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County

1 reference

12 December 2020

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

12 December 2020

Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group

1 reference

12 December 2020

Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis

1 reference

12 December 2020

[Infliximab-induced hepatitis in a patient with Crohn's disease]

1 reference

12 December 2020

Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab

1 reference

12 December 2020

Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab

1 reference

12 December 2020

Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

1 reference

12 December 2020

Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab

1 reference

12 December 2020

Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis

1 reference

12 December 2020

Etanercept tolerance in a patient with previous infliximab-induced hepatitis

1 reference

12 December 2020

10.3748/WJG.V20.I46.17352

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

25516646

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25516646%20AND%20SRC:MED&resulttype=core&format=json